Ilenia Calcaterra: Innovation In Rare Diseases Is Never Abstract
Ilenia Calcaterra, Consultant Physician in Internal Medicine and Assistant Professor at the University of Naples Federico II, shared on LinkedIn, adding:
”Today is Rare Disease Day.
I work actively in the field of rare diseases, where progress often depends on rigorous research, multidisciplinary collaboration, and responsible clinical decision-making.
This image captures a milestone in our clinical practice: in September 2024, we administered the first gene therapy for Hemophilia A in our center.
Innovation in rare diseases is never abstract.
It is built carefully, through evidence, integrity, and high standards especially when patient numbers are small and every decision carries weight.
Raising awareness matters.
Building reliable evidence matters even more.
In rare diseases, small numbers require higher standards not lower ones.”
Stay updated with Hemostasis Today.
-
Jun 21, 2026, 19:19Tribikram Panda: Ensuring Global Equity in Management of Sickle Cell Disease
-
Jun 21, 2026, 19:15Vicken Babikian Receives Mkhitar Heratsi Medal – AAHPO
-
Jun 21, 2026, 19:11Joaqim Meireles-Brandao: Once Disease is Established, All That Remains is to Mitigate the Consequences
-
Jun 21, 2026, 18:54A Comprehensive Review of Hemophilia A and B – Journal of Thrombosis and Haemostasis
-
Jun 21, 2026, 18:54Maxime Dely: Raising Awareness and Improving Diagnosis of Sickle Cell Disease in France
-
Jun 21, 2026, 18:08Roberta Gualtierotti: Point-of-Care SPR Device for Rapid Detection of Anti-PEG Antibodies
-
Jun 21, 2026, 17:59Fakhrul Abedin Jon: Exploring Types of Brain Bleeding
-
Jun 21, 2026, 17:00Jeffrey Schnur: Advanced Treatment Strategies for Deep Vein Thrombosis and Pulmonary Embolism
-
Jun 21, 2026, 16:53Matteo Foschi: When Should We Restart Anticoagulation After a Breakthrough Ischemic Stroke?